- Harris, Trump and Biden mark Oct. 7 attacks as US election looms
- Oil prices extend gains on Mideast tensions, Wall Street falls
- US judge orders Google to open Android to rival app stores
- On attacks anniversary, Israel fights 'sacred' multi-front war
- Nobel scientist uncovered tiny genetic switches with big potential
- Grammy-winning Cissy Houston, mother of Whitney, dies at 91
- UN biodiversity summit in Colombia aims to turn words into action
- Georgia Supreme Court reinstates six-week abortion ban
- 'Dark day': Victims mourned around the globe on Oct. 7 anniversary
- On attacks anniversary, Israel fights multi-front war
- Mexican mayor murdered days after taking office
- Intensifying to Category 5, Hurricane Milton targets Florida
- Mission to probe smashed asteroid launches despite hurricane
- Biden, Harris mark Oct. 7 with call for Mideast peace
- Dupont set for Toulouse return after post-Olympic holiday
- French rugby bosses tighten discipline after nightmare Argentina tour
- Oil prices extend gains on Mideast tensions, Wall Street slips
- Visitors to get rare view of Rome's Trevi Fountain
- Europe's asteroid mission Hera launches despite hurricane
- Man City and Premier League both claim victory in legal case
- Deschamps delight as 'light back on' for Pogba after doping ban
- Biden, Harris urge Mideast peace on Oct. 7 anniversary
- Neeskens, tough midfielder in Cruyff's Ajax and Dutch teams
- UN warns world's water cycle becoming ever more erratic
- Oil prices extend gains on Mideast tensions, Wall Street retreats
- Ex-Dutch football star Johan Neeskens dies
- Man Utd battling to improve fortunes, says Evans
- What is microRNA? Nobel-winning discovery explained
- Masood, Abdullah centuries lift Pakistan to 328-4 in first England Test
- Hurricane Milton strengthens fast, threatens Mexico, Florida
- Tunisia's President Saied set for landslide election win
- Barca hoping to return to Camp Nou 'by end of year'
- Trump to open second golf course at Scotland resort in summer 2025
- Super-sub Jhon Duran rewarded with new Aston Villa deal
- US duo win Nobel for gene regulation breakthrough
- Masood hits first ton for four years to power Pakistan to 233-1
- Fritz wins delayed match to reach Shanghai Masters third round
- Naomi Osaka pulls out of Japan Open with back injury
- Weather may delay launch of mission to study deflected asteroid
- China to flesh out economic stimulus plans after bumper rally
- Artist Marina Abramovic hopes first China show offers tech respite
- Asian markets track Wall St rally on US jobs data
- Pakistan 122-1 at lunch in first England Test
- Kazakhs approve plan for first nuclear power plant
- World marks anniversary of Oct. 7 attack on Israel
- 'Second family': tennis stars hunt winning formula with new coaches
- Philippines, South Korea agree to deepen maritime cooperation
- Mexico mayor murdered days after taking office
- Sardinia's sheep farmers battle bluetongue as climate warms
- Japan govt admits doctoring 'untidy' cabinet photo
RBGPF | -1.97% | 58.94 | $ | |
BCC | 1.68% | 141.27 | $ | |
NGG | -1.56% | 65.48 | $ | |
CMSC | -0.53% | 24.57 | $ | |
RYCEF | -1.45% | 6.88 | $ | |
BCE | -0.54% | 33.53 | $ | |
GSK | -0.49% | 38.63 | $ | |
SCS | -0.15% | 12.95 | $ | |
RIO | -0.11% | 69.62 | $ | |
JRI | -0.76% | 13.18 | $ | |
RELX | -0.54% | 46.04 | $ | |
CMSD | -0.09% | 24.79 | $ | |
VOD | 0.31% | 9.69 | $ | |
AZN | -0.78% | 76.87 | $ | |
BTI | -0.26% | 35.2 | $ | |
BP | 0.78% | 33.14 | $ |
New 'vaccine-like' HIV drug could cost just $40: researchers
A new "vaccine-like" HIV drug that currently costs over $40,000 per person a year could be made for as little as $40, researchers estimated on Tuesday.
The antiretroviral drug Lenacapavir, developed by US pharmaceutical giant Gilead, has been hailed as a potential game-changer in the fight against HIV.
Early trials have found the treatment is 100 percent effective in preventing HIV infection. And it only needs to be injected twice a year, making the drug far easier to administer than current regimens requiring daily pills.
"It's like having a vaccine basically," Andrew Hill, a researcher at the UK's Liverpool University, told AFP.
The treatment currently costs patients over $40,000 a year in a range of countries including the United States, France, Norway and Australia.
New research, which Hill presented at the International AIDS Conference in Munich on Tuesday, looked into how much the cost of making the drug could come down if Gilead allowed for cheaper generic versions to be manufactured.
A year's worth of the drug could be made for as little as $40 -- 1,000 times less than the current price -- according to the research, which has not been peer reviewed.
This price was based on production volumes equal to treating 10 million people.
If the drug was given to people at high risk of contracting HIV -- such as gay or bisexual men, sex workers, prisoners or notably young women in Africa -- it could "basically shut down HIV transmission," Hill emphasised.
"We could actually control the epidemic."
There were 1.3 million new HIV infections last year, while 39 million people are living with the virus, according to the World Health Organization.
- 'Opportunity to save the world' -
To estimate the cost, the researchers studied shipments of raw materials of the drug, and spoke to large generic manufacturers in China and India that already make its "building blocks," Hill said.
The international team of researchers has been proven right about similar estimates in the past, he added.
A decade ago, the team said that the cost of making Gilead's hepatitis C drug -- then priced at $84,000 a patient -- could plummet to $100 if generics were allowed.
"Now it costs just under $40 to cure Hepatitis C," Hill said.
The new research was announced a day after UNAIDS chief Winnie Byanyima called on Gilead to "make history" by opening up Lenacapavir to the UN-backed Medicines Patent Pool, which would allow generics to be sold under licence in low- and middle-income nations.
"Gilead has an opportunity to save the world," she told AFP.
A Gilead spokesperson told AFP that the firm is still waiting on phase 3 clinical trial data on using Lenacapavir to prevent HIV, so "it is too early to state" what it could have in the future.
The firm has a strategy to "supply high-quality, low-cost versions of Lenacapavir" in countries "where the need is greatest," the spokesperson said.
It is also "moving with urgency" to negotiate contracts for a voluntary licencing programme to "expedite access to those versions of lenacapavir in high-incidence, resource-limited countries," the spokesperson added.
T.Ward--AMWN